EGb 761<sup>®</sup> Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer’s Dementia—Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial
Following reports of bleeding upon Ginkgo intake, we assessed whether Ginkgo extract EGb 761<sup>®</sup> affects coagulation or platelet function or increases the risk of bleeding. In a double-blind, placebo-controlled trial, prothrombin time, activated partial thromboplastin time, inter...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Healthcare |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9032/9/12/1678 |
| _version_ | 1797504118135193600 |
|---|---|
| author | Charlotte Kloft Robert Hoerr |
| author_facet | Charlotte Kloft Robert Hoerr |
| author_sort | Charlotte Kloft |
| collection | DOAJ |
| description | Following reports of bleeding upon Ginkgo intake, we assessed whether Ginkgo extract EGb 761<sup>®</sup> affects coagulation or platelet function or increases the risk of bleeding. In a double-blind, placebo-controlled trial, prothrombin time, activated partial thromboplastin time, international normalized ratio and bleeding time were measured in patients with Alzheimer’s dementia at baseline, weeks 6 and 26. A total of 513 patients were randomized to 120 mg (<i>n</i> = 169) or 240 mg EGb 761<sup>®</sup> (<i>n</i> = 170) or placebo (<i>n</i> = 174). No relevant changes were found for coagulation parameters and bleeding time. Numbers of bleeding-related adverse events were similar in all groups. Concomitant intake of acetylsalicylic acid was documented for 68 patients in the placebo group and 105 in the EGb 761<sup>®</sup> groups. Within these groups, the means at baseline and week 26 differed by less than 1 unit for prothrombin time and bleeding time and less than 0.1 unit for international normalized ratio. Data on warfarin treatment in nine patients each taking placebo or EGb 761<sup>®</sup> did not indicate enhancement of warfarin effects by EGb 761<sup>®</sup>. No evidence was found that EGb 761<sup>®</sup> affects hemostasis or increases the bleeding risk. No pharmacodynamic interactions with warfarin or acetylsalicylic acid were found. |
| first_indexed | 2024-03-10T04:00:06Z |
| format | Article |
| id | doaj.art-149bbc69113f4f92ae9382d308dca10c |
| institution | Directory Open Access Journal |
| issn | 2227-9032 |
| language | English |
| last_indexed | 2024-03-10T04:00:06Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Healthcare |
| spelling | doaj.art-149bbc69113f4f92ae9382d308dca10c2023-11-23T08:34:01ZengMDPI AGHealthcare2227-90322021-12-01912167810.3390/healthcare9121678EGb 761<sup>®</sup> Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer’s Dementia—Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled TrialCharlotte Kloft0Robert Hoerr1Institute of Pharmacy, Freie Universität Berlin, 12169 Berlin, GermanyResearch & Development, Dr. Willmar Schwabe GmbH & Co. KG, 76227 Karlsruhe, GermanyFollowing reports of bleeding upon Ginkgo intake, we assessed whether Ginkgo extract EGb 761<sup>®</sup> affects coagulation or platelet function or increases the risk of bleeding. In a double-blind, placebo-controlled trial, prothrombin time, activated partial thromboplastin time, international normalized ratio and bleeding time were measured in patients with Alzheimer’s dementia at baseline, weeks 6 and 26. A total of 513 patients were randomized to 120 mg (<i>n</i> = 169) or 240 mg EGb 761<sup>®</sup> (<i>n</i> = 170) or placebo (<i>n</i> = 174). No relevant changes were found for coagulation parameters and bleeding time. Numbers of bleeding-related adverse events were similar in all groups. Concomitant intake of acetylsalicylic acid was documented for 68 patients in the placebo group and 105 in the EGb 761<sup>®</sup> groups. Within these groups, the means at baseline and week 26 differed by less than 1 unit for prothrombin time and bleeding time and less than 0.1 unit for international normalized ratio. Data on warfarin treatment in nine patients each taking placebo or EGb 761<sup>®</sup> did not indicate enhancement of warfarin effects by EGb 761<sup>®</sup>. No evidence was found that EGb 761<sup>®</sup> affects hemostasis or increases the bleeding risk. No pharmacodynamic interactions with warfarin or acetylsalicylic acid were found.https://www.mdpi.com/2227-9032/9/12/1678GinkgoEGb 761<sup>®</sup>blood coagulationbleeding timeacetylsalicylic acidwarfarin |
| spellingShingle | Charlotte Kloft Robert Hoerr EGb 761<sup>®</sup> Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer’s Dementia—Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial Healthcare Ginkgo EGb 761<sup>®</sup> blood coagulation bleeding time acetylsalicylic acid warfarin |
| title | EGb 761<sup>®</sup> Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer’s Dementia—Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial |
| title_full | EGb 761<sup>®</sup> Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer’s Dementia—Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial |
| title_fullStr | EGb 761<sup>®</sup> Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer’s Dementia—Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial |
| title_full_unstemmed | EGb 761<sup>®</sup> Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer’s Dementia—Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial |
| title_short | EGb 761<sup>®</sup> Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer’s Dementia—Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial |
| title_sort | egb 761 sup r sup does not affect blood coagulation and bleeding time in patients with probable alzheimer s dementia secondary analysis of a randomized double blind placebo controlled trial |
| topic | Ginkgo EGb 761<sup>®</sup> blood coagulation bleeding time acetylsalicylic acid warfarin |
| url | https://www.mdpi.com/2227-9032/9/12/1678 |
| work_keys_str_mv | AT charlottekloft egb761supsupdoesnotaffectbloodcoagulationandbleedingtimeinpatientswithprobablealzheimersdementiasecondaryanalysisofarandomizeddoubleblindplacebocontrolledtrial AT roberthoerr egb761supsupdoesnotaffectbloodcoagulationandbleedingtimeinpatientswithprobablealzheimersdementiasecondaryanalysisofarandomizeddoubleblindplacebocontrolledtrial |